Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli. | Ocular Therapeutix is making sure its corporate vision ...

Merck KGaA executive Renee Connolly and Gen Z recording artist Lola Young joined Havas Health and Creative Networks CEO Donna ...

Two and a half years into his tenure as Teva’s CEO, Richard Francis is breaking down the strategy that’s powered the company ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

Robert F. Kennedy Jr.’s revamped Advisory Committee on Immunization Practices has struck its first blow against established ...

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...

U.S. multinational company Abbott entered a partnership with Abu Dhabi's Department of Health to manufacture medicines in the ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...